Overview

A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study was to evaluate the safety and tolerability of nasal glucagon (NG). The study drug was delivered into the participant's nostril (intranasally) or was given as an injection just under the skin (subcutaneously) once in each of four study periods. The study lasted about 23 days for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Locemia Solutions ULC
Treatments:
Glucagon
Glucagon-Like Peptide 1